453 related articles for article (PubMed ID: 26178788)
1. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Kuter I; Gee JM; Hegg R; Singer CF; Badwe RA; Lowe ES; Emeribe UA; Anderson E; Sapunar F; Finlay P; Nicholson RI; Bines J; Harbeck N
Breast Cancer Res Treat; 2012 May; 133(1):237-46. PubMed ID: 22286314
[TBL] [Abstract][Full Text] [Related]
3. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.
Chan HJ; Li H; Liu Z; Yuan YC; Mortimer J; Chen S
Oncotarget; 2015 Sep; 6(28):25815-27. PubMed ID: 26158350
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
Blancas I; Fontanillas M; Conde V; Lao J; Martínez E; Sotelo MJ; Jaen A; Bayo JL; Carabantes F; Illarramendi JJ; Gordon MM; Cruz J; García-Palomo A; Mendiola C; Pérez-Ruiz E; Bofill JS; Baena-Cañada JM; Jáñez NM; Esquerdo G; Ruiz-Borrego M
Clin Transl Oncol; 2018 Jul; 20(7):862-869. PubMed ID: 29178019
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B; Psenak O; Mayer P; Moik M; Namberger K; Hauser-Kronberger C; Greil R
Breast Cancer Res Treat; 2007 Nov; 106(1):105-12. PubMed ID: 17295045
[TBL] [Abstract][Full Text] [Related]
6. Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Blancas I; Olier C; Conde V; Bayo JL; Herrero C; Zarcos-Pedrinaci I; Carabantes F; Baena-Cañada JM; Cruz J; Ruiz-Borrego M
Sci Rep; 2021 Feb; 11(1):4274. PubMed ID: 33608590
[TBL] [Abstract][Full Text] [Related]
7. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.
Giuliano M; Hu H; Wang YC; Fu X; Nardone A; Herrera S; Mao S; Contreras A; Gutierrez C; Wang T; Hilsenbeck SG; De Angelis C; Wang NJ; Heiser LM; Gray JW; Lopez-Tarruella S; Pavlick AC; Trivedi MV; Chamness GC; Chang JC; Osborne CK; Rimawi MF; Schiff R
Clin Cancer Res; 2015 Sep; 21(17):3995-4003. PubMed ID: 26015514
[TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
Johnston SR; Martin LA; Head J; Smith I; Dowsett M
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):173-81. PubMed ID: 15996863
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
11. Prolonged time to progression with fulvestrant for metastatic breast cancer.
Mello CA; Chinen LT; da Silva SC; do Nascimento Matias C; Benevides CF; Gimenes DL; Fanelli MF
Med Oncol; 2011 Jun; 28(2):416-9. PubMed ID: 20306159
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
Ciruelos E; Pascual T; Arroyo Vozmediano ML; Blanco M; Manso L; Parrilla L; Muñoz C; Vega E; Calderón MJ; Sancho B; Cortes-Funes H
Breast; 2014 Jun; 23(3):201-8. PubMed ID: 24589524
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Ma CX; Sanchez C; Gao F; Crowder R; Naughton M; Pluard T; Creekmore A; Guo Z; Hoog J; Lockhart AC; Doyle A; Erlichman C; Ellis MJ
Clin Cancer Res; 2016 Jun; 22(11):2650-8. PubMed ID: 26783290
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC
Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005
[TBL] [Abstract][Full Text] [Related]
15. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
17. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer.
Bartsch R; Mlineritsch B; Gnant M; Niernberger T; Pluschnig U; Greil R; Wenzel C; Sevelda P; Thaler J; Rudas M; Pober M; Zielinski CC; Steger GG;
Breast Cancer Res Treat; 2009 May; 115(2):373-80. PubMed ID: 18661231
[TBL] [Abstract][Full Text] [Related]
18. [Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].
Vanacker H; Bally O; Kassem L; Tredan O; Heudel P; Bachelot T
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S47-52. PubMed ID: 26118876
[TBL] [Abstract][Full Text] [Related]
19. A good drug made better: the fulvestrant dose-response story.
Robertson JF; Lindemann J; Garnett S; Anderson E; Nicholson RI; Kuter I; Gee JM
Clin Breast Cancer; 2014 Dec; 14(6):381-9. PubMed ID: 25457991
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
